文献速递神经肿瘤神经重症

多模态成像绘制免疫治疗分布作为胶质瘤预测标志物

Multimodality mapping of immunotherapy distribution as a predictive marker in glioma.
PubMed 文献 · Neuro Oncol · 2026-01-01

研究开发MRI-光片显微镜平台(MR-LSM)在两种免疫健全胶质瘤模型中监测免疫治疗细胞水平分布,发现SB28模型耐药由微血管病理和药物脱靶驱动,VEGF抑制联合放疗与双免疫治疗可逆转耐药;在N2M2/NOA20试验中验证水肿和微血管病理与检查点免疫治疗胶质母细胞瘤患者不良预后相关,无水肿患者PFS增加。

要点

  • MR-LSM平台可在细胞水平绘制免疫治疗药物在胶质瘤中的分布。
  • 微血管病理和瘤周水肿导致药物脱靶并驱动免疫治疗耐药。
  • VEGF抑制联合放疗与双免疫治疗可克服耐药并延长生存。

核心结论

  • 多模态成像平台可绘制胶质瘤药物递送分布,水肿和微血管病理与检查点免疫治疗预后不良相关。

研究设计与样本

  • 开发MRI-光片显微镜平台(MR-LSM),在Gl261和SB28两种免疫健全胶质瘤模型中监测免疫治疗细胞水平分布。
  • 对多中心N2M2/NOA20试验中MGMT未甲基化胶质母细胞瘤患者的atezolizumab亚组进行CNN分析并与无进展生存期相关。

主要发现

  • SB28胶质瘤免疫原性差且对CDNP-R848纳米颗粒递送的TLR7靶向治疗耐药。
  • SB28耐药由微血管病理、血管源性水肿及药物脱靶至瘤周水肿和白质束驱动。
  • VEGF抑制联合放疗和靶向先天免疫(CDNP-R848)与适应性免疫(抗CTLA-4)的双免疫治疗可打破耐药、提高生存并逆转药物脱靶。
  • 肿瘤控制机制涉及血管正常化、CD8+ T细胞浸润增强、髓系细胞促炎转变及IL-12/IL-13上调。
  • N2M2/NOA20转化分析验证水肿和微血管病理与检查点免疫治疗胶质母细胞瘤患者不良预后相关,无水肿患者PFS增加。

临床怎么用

  • 水肿和微血管病理影像特征可能作为检查点免疫治疗胶质母细胞瘤患者的预后标志物。
  • 针对血管正常化的联合策略可能改善免疫治疗药物递送并克服耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Scarce T cell infiltration, immunosuppressive tumor-associated macrophages, and ineffective drug delivery drive glioma progression and limit treatment efficacy. Mapping immunotherapy distribution by multimodality imaging might be a biomarker that could aid tumor monitoring and guide therapy development. METHODS: To assess drug delivery, we developed a MRI-lightsheet microscopy platform (MR-LSM) to monitor immunotherapy at the cellular level in two immunocompetent glioma models (Gl261, SB28). The atezolizumab (PD-L1 inhibitor) subgroup of the multicenter N2M2/NOA20 trial in MGMT unmethylated GBM patients was assessed by CNN analysis and correlated to progression-free survival. RESULTS: In contrast to the conventional Gl261 glioma model, SB28 gliomas are characterized by poor immunogenicity and resistance to Toll-like receptor (TLR) 7 targeted therapy delivered by CDNP-R848 nanoparticles. SB28 resistance is driven by microvascular pathology, vasogenic edema, and drug off-targeting to peritumoral edema and white matter tracts. Vascular endothelial growth factor (VEGF) inhibition in conjunction with irradiation and dual immunotherapy (DIR) targeting innate (CDNP-R848) and adaptive immunity (anti-CTLA-4) breaks resistance, increases survival, and reverses drug off-targeting. Mechanistically, tumor control is orchestrated by vascular normalization, enhanced CD8+ T cell influx, and a proinflammatory shift of myeloid cells along with strong IL-12/IL-13 upregulation. In a translational analysis of the multicenter N2M2/NOA20 trial, we validate that edema and microvascular pathology are associated with poor prognosis in glioblastoma patients treated with checkpoint immunotherapy and that patients without edema have increased PFS. CONCLUSIONS: . We develop a customizable imaging platform to map drug delivery to glioma with broad applicability in neuroscience and neuro-oncology.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Scheck JG, Boztepe B, Kernbach JM, et al. Multimodality mapping of immunotherapy distribution as a predictive marker in glioma. Neuro Oncol. 2026. PMID: 41476211. doi:10.1093/neuonc/noaf295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。